Physician profile
Kwan Yee
NPI 1104817618
$8,783.54
in general payments reported to CMS, 2019-2025
45 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $1,024 · 2021: $1,377 · 2022: $1,312 · 2023: $1,230 · 2024: $1,333 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,145.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,094.91 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,223.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $894.31 | 2020-2025 | Ozempic, Rybelsus |
| Madrigal Pharmaceuticals | $651.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $475.09 | 2019-2024 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.07 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $290.87 | 2022-2025 | |
| Glaxosmithkline, LLC. | $269.19 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $260.85 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $192.54 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $188.41 | 2019-2024 | |
| Abbvie INC. | $182.42 | 2021-2025 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $155.69 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $152.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.29 | 2021-2025 | Xifaxan |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kwan Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.